Unlock stock picks and a broker-level newsfeed that powers Wall Street.
Next Green Wave Achieves Operational Milestones For Intrexon's Botticelli(TM) Cannabis Plantlet Production

NGW Nursery Capacity Established and Second Harvest Completed

Vancouver, British Columbia--(Newsfile Corp. - September 24, 2019) - Next Green Wave Holdings Inc. (CSE: NGW) (OTCQX: NXGWF) ("Next Green Wave", "NGW" or the "Company") announces that it has completed the installation and activation of its research and innovation laboratory under license from biotech leader Intrexon (NASDAQ: XON). Under the agreement, these milestones will advance Intrexon's Botticelli™ next generation plant (non-GMO) propagation platform and begin the rapid optimization and production of Next Green Wave's proprietary cannabis cultivars.

Per their agreement announced on March 22, 2019, Intrexon and NGW have achieved the following milestones:

  • Optimization of Botticelli™ protocol for Next Green Wave's hemp CBD strains.

  • Completion of tissue culture lab at NGW production site to begin Botticelli™ optimization of NGW's proprietary nursery stock.

Cannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/847210535a1bac1e82a1f712107b85b5
Cannot view this image? Visit: https://media.zenfs.com/en-us/newsfile_64/847210535a1bac1e82a1f712107b85b5



Figure 1: Botticelli™ laboratory at NGW facility

To view an enhanced version of Figure 1, please visit:
https://orders.newsfilecorp.com/files/6127/48078_newgreen2.jpg

"The opening of this research facility is a huge milestone on our path to establish a world-class cannabis nursery. Combining Intrexon's proprietary Botticelli™ tissue culture platform with NGW's proprietary stock and cultivation team, we aim to push the limits of the current cannabis performance paradigm. After a successful optimization phase, we will begin the Botticelli™ plantlet production for our own internal cultivation and also supply our industry leading plantlets to other licensed cultivators in California," stated Michael Jennings, CEO of NGW.

In the U.S. market, legal cannabis revenue is projected to exceed $31.3 billion by 2022*, with California representing around a third of that market. Current cannabis cultivation is predominantly dependent on clonal propagation by using cuttings of mother plants. This creates barriers to meeting product demand and also risk of disease susceptibility. In addition, plants derived from repeated cuttings lose vigor in performance. Botticelli offers potential for a sustainable, scalable, and more economical solution than conventional clones.

"We are excited to have achieved optimization of Botticelli™ protocol for hemp CBD strains, as a proxy for cannabis, and feel confident about the potential of our platform for cannabis cultivation. We are looking forward to seeing the Botticelli™ platform enabled and integrated with NGW's production, validating its value-add for the cannabis industry," commented Sekhar Boddupalli, President, Intrexon's Ag Bio Division.